Article Sidebar

PDF
Issue: Vol. 523 No. 2 (2023)
Section: Các bài báo
DOI: 10.51298/vmj.v523i2.4513
Date Published: 28/02/2023
Views 562
Downloads 393
How to Cite
Phan, T. M. H., Lê, T. T. X., Nguyễn, V. T., Lê, T. T. H., Nguyễn, T. N., Hoàng, D. L., Hoàng, L. Q., Lương, H. P., An, H. L., Phạm , T. Q., Nguyễn, N. A., Nguyễn, T. T., Tạ, T. K. N., Phạm , T. H., Nguyễn, Q. D., & Nguyễn, T. Q. (2023). PREVALENCE OF ADVERSE EFFECTS OF COVID-19 PFIZER VACCINE AMONG ADULTS AT HA NOI MEDICAL UNIVERSITY, 2021. Vietnam Medical Journal, 523(2). https://doi.org/10.51298/vmj.v523i2.4513

PREVALENCE OF ADVERSE EFFECTS OF COVID-19 PFIZER VACCINE AMONG ADULTS AT HA NOI MEDICAL UNIVERSITY, 2021

Thị Mai Hương Phan1, Thị Thanh Xuân Lê1, Văn Thành Nguyễn1, Thị Thanh Hà Lê1, Thúy Nam Nguyễn1, Diệu Linh Hoàng1, Long Quân Hoàng1, Huyền Phương Lương1, Hồng Liên An1, Thị Quân Phạm 1, Ngọc Anh Nguyễn2, Thanh Thảo Nguyễn1, Thị Kim Nhung Tạ3, Thị Hiền Phạm 1, Quốc Doanh Nguyễn1, Thị Quỳnh Nguyễn1,
1 Hanoi medical university
2 Hanoi medical univesity
3 Hanoi medicla university

Main Article Content

Abstract

Objectives: to describe the prevalence of adverse effects of the Covid-19 Pfizer vaccine among adults at Ha Noi Medical University in 2021. Method: A cross-sectional study was conducted on 813 people from October 2021 to October 2022. Results: the rate of local effects after in 1st dose was 14.8%, 2nd dose was 40.2%. Common effects were tiredness (1st dose:10.3%, 2nd dose: 38.0 %), increasing pain impress (1st dose:7.8%, 2nd dose: 18.0 %), fever < 38.5°C (1st dose: 3.7%, 2nd dose: 19.8 %). The dangerous effects were very low. The adverse effects of Covid 1-9 Pfizer vaccine usually occurred from 1 to 24 hours after vaccination. Conclusion: The rate of the adverse effects of Covid-19 Pfizer vaccine among adults at Ha Noi Medical University in 2021 was relatively high, but mainly common effects such as fever, tiredness and increasing pain impress.

Keywords

adverse effects, Covid-19 Pfizer vaccine, Ha Noi Medical University

Article Details

References

1. World Heatlth Organization. The Pfizer BioNTech (BNT162b2) COVID-19 vaccine: What you need to know. Accessed 9/11/2022, https://www.who.int/news-room/feature-stories/detail/who-can-take-the-pfizer-biontech-covid-19--vaccine-what-you-need-to-know
2. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. The New England journal of medicine. Dec 31 2020;383(27):2603-2615. doi:10.1056/ NEJMoa2034577
3. Andrea Ossato, Roberto Tessari, Carlotta Trabucchi, et al. Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021. European Journal of Hospital Pharmacy. 2021;
4. Qianhui Wu, Matthew Z Dudley, Xinghui Chen, et al. Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC medicine. 2021;19(1):1-16.
5. Tran VN, Nguyen HA, Le TTA, et al. Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021. Vaccine. Oct 22 2021;39(44):6485-6491. doi:10.1016/j.vaccine.2021.09.060
6. Francisco Tsz Tsun Lai, Miriam Tim Yin Leung, Edward Wai Wa Chan, et al. Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): a prospective cohort study with intensive monitoring. Vaccine. 2022;40(10):1390-1396.
7. Giancarlo Ripabelli, Manuela Tamburro, Nicandro Buccieri, et al. Active surveillance of adverse events in healthcare workers recipients after vaccination with COVID-19 BNT162b2 vaccine (Pfizer-BioNTech, Comirnaty): a cross-sectional study. Journal of Community Health. 2022;47(2):211-225.